Free Trial

ADMA Biologics (ADMA) Earnings Date, Estimates & Call Transcripts

ADMA Biologics logo
$17.40 -0.50 (-2.79%)
(As of 12/20/2024 05:31 PM ET)

ADMA Biologics Latest Earnings Summary

Actual EPS
(Nov. 7)
$0.15 Beat By $0.02
Consensus EPS
(Nov. 7)
$0.13

ADMA Biologics released Q3 2024 earnings on November 7, 2024, reporting an EPS of $0.15, which beat analysts' consensus estimates of $0.13 by $0.02. Quarterly revenue was reported to be $119.84 million, above the consensus estimate of $107.25 million. With a trailing EPS of $0.28 and a P/E Ratio of 62.14, ADMA Biologics' earnings are expected to grow 50.00% next year, from $0.52 to $0.78 per share.

Get ADMA Biologics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADMA Biologics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ADMA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADMA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ADMA Biologics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241$0.05$0.05$0.05
Q2 20241$0.07$0.07$0.07
Q3 20241$0.13$0.13$0.13
Q4 20241$0.19$0.19$0.19
FY 20244$0.44$0.44$0.44
Q1 20251$0.20$0.20$0.20
Q2 20251$0.21$0.21$0.21
Q3 20251$0.22$0.22$0.22
Q4 20251$0.24$0.24$0.24
FY 20254$0.87$0.87$0.87

ADMA Biologics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/7/2024Q3 2024$0.13$0.15+$0.02$0.15$107.25M$119.84M
8/8/2024Q2 2024$0.08$0.13+$0.05$0.13$86.44M$107.20M
5/9/2024Q1 2024$0.05$0.08+$0.03$0.08$77.28M$81.90M
2/28/2024Q4 2023$0.02$0.04+$0.02$0.16$73.50M$73.90M
11/8/2023Q3 2023-$0.01-$0.01-$0.01$62.13M$67.30M
8/9/2023Q2 2023-$0.02-$0.02--$0.01$55.45M$60.12M
Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.
5/10/2023Q1 2023-$0.05-$0.03+$0.02-$0.03$51.35M$56.91M
3/23/2023Q4 2022-$0.06-$0.06--$0.06$49.02M$49.98M

ADMA Biologics Earnings - Frequently Asked Questions

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on ADMA's earnings history.

ADMA Biologics updated its FY 2024 earnings guidance on Thursday, November, 7th. The company issued revenue guidance of $415.0 million-, compared to the consensus revenue estimate of $406.1 million.

In the previous quarter, ADMA Biologics (NASDAQ:ADMA) reported $0.15 earnings per share (EPS) to beat the analysts' consensus estimate of $0.13 by $0.02. Learn more on analysts' earnings estimate vs. ADMA's actual earnings.

The conference call for ADMA Biologics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for ADMA Biologics's latest earnings report can be read online.
Read Transcript

ADMA Biologics (NASDAQ:ADMA) has a recorded annual revenue of $382.81 million.

ADMA Biologics (NASDAQ:ADMA) has a recorded net income of -$28.24 million. ADMA has generated $0.28 earnings per share over the last four quarters.

ADMA Biologics (NASDAQ:ADMA) has a trailing price-to-earnings ratio of 62.14 and a forward price-to-earnings ratio of 33.46.

ADMA Biologics's earnings are expected to grow from $0.52 per share to $0.78 per share in the next year, which is a 50.00% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:ADMA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners